Peplin Initiates Phase 3 Clinical Trials with PEP005 Gel in AK on Face and Scalp read more
Peplin's Positive Phase II AK Trial Results Published in JAAD read more
Positive Results for Peplin's First Phase III AK Trial read more
Peplin Results for the Quarter Ended 31 March 2009 read more
| cell proliferation | Increase in the number of cells as a result of cell division |
| chemotherapy | The use of chemical agents in the treatment or control of disease or mental disorders |
| clinical trials | Medical research studies conducted on human subjects to answer scientific questions and to find better ways to prevent, detect or treat diseases |
| efficacy | The ability of a drug to control or cure an illness or disease |
| FDA | Food and Drug Administration |
| formulation | Incorporation of a drug into a relevant delivery vehicle, such as a gel |
| GMP | Good Manufacturing Process |
| intravenous (IV) | Situated within, performed within, occurring within, or administered by entering a vein - injection of a drug into the bloodstream through a vein |
| intra-cavitary (IC) | Situated or occurring within a body cavity (i.e. treatment characterized by the insertion of substances in a cavity) |
| IND | Investigational new drug |
| kinase | An enzyme that catalyzes the transfer of phosphate groups from a high-energy phosphate-containing molecule (as ATP or ADP) to a substrate |
| malignant | Cancerous - of unfavorable prognosis |
| melanocytes | An epidermal cell that produces melanin |
| metastases, metastasise | Transfer of a disease-producing agency (e.g. cancer cells) from an original site of disease to another part of the body with development of a similar lesion in a new location |
| mutation | A relatively permanent change in hereditary material (gene) involving a physical change in chromosome relations |
| pathway | A system of proteins that work together |
| pharmacokinetics | The study of the bodily absorption, distribution, metabolism and excretion of drugs |
| pharmacology | Evaluation of the activity of the drug in various cell systems and animal models of the disease |
| phase I | Clinical trial designed to determine the safety and appropriate dose |
| phase II | Clinical trial designed to measure the safety and efficacy |
| phase III | Clinical trial designed to test new treatment and measure efficacy as well as safety as compared to the standard of care |
| progression | A trend or shift toward a high, more severe state - increase of tumour size (opposite of regression) |
| receptor | A chemical group or molecule (as a protein) on the cell surface or in the cell interior that has an affinity for a specific chemical group, molecule, or virus |
| regimen | A systematic plan designed to improve and maintain the health of a patient |
| regression | A trend or shift toward a lower, less severe or less perfect state - reduction in the size of tumour (opposite of progression) |
| therapeutic | Of or relating to the treatment of disease or disorders by remedial agents or methods |
| therapy (therapies) | Treatment(s) |
| toxicity | The quality, state, or relative degree of being toxic or poisonous |
| toxicology | Evaluation of the safety profile of a drug |
| tumour | An abnormal benign or malignant mass of tissue that is not inflammatory, arises without obvious cause from cells of preexistent tissue, and possesses no physiological function |